Bronchodilators

Effects of combined tiotropium/olodaterol on dynamic lung hyperinflation evaluated by the incremental hyperventilation method
Shohei Kawachi, Keisaku Fujimoto

European Respiratory Journal Sep 2019, 54 (suppl 63) PA3384; DOI: 10.1183/13993003.congress-2019.PA3384
Efficacy evaluation, time estimates for method of bronchial valve closure (BVC) in the treatment of patients with double infections of immunodeficiency virus / tuberculosis (HI virus/TB)
Danil Iurev, Sergey Smerdin, Mikhail Toschevikov, Diana Akimova

European Respiratory Journal Sep 2019, 54 (suppl 63) PA3128; DOI: 10.1183/13993003.congress-2019.PA3128
Improving symptomology in COPD: which therapy would you choose, a brochodilator or pulmonary rehabilitation?
Sarah Edwards, Theresa Harvey-Dunstan, Ruth Tal-Singer, Matthew Allinder, Michael Polkey, Michael Steiner, Mike Morgan, Sally Singh

European Respiratory Journal Sep 2019, 54 (suppl 63) PA3416; DOI: 10.1183/13993003.congress-2019.PA3416
Relative bioavailability of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI) administered with and without a spacer in healthy adults
Paul Dorinsky, Paolo Depetrillo, Kiernan Deangelis, Roopa Trivedi, Mindy Mo, Shaila Ballal, Michael Gillen

European Respiratory Journal Sep 2019, 54 (suppl 63) PA3376; DOI: 10.1183/13993003.congress-2019.PA3376
Significance of reversibility in Lower Limit of Normal defined obstruction – The PneumoLaus study
Brice Touilloux, Alexandra Lenoir, Jean-William Fitting, Peter Vollenweider, Laurent P. Nicod

European Respiratory Journal Sep 2019, 54 (suppl 63) PA3387; DOI: 10.1183/13993003.congress-2019.PA3387
The bronchodilator response and clinical characteristics of patients with bronchiectasis
Wilson Goh, Ee Chen Jaclyn Tan, Xiao Na Wang, Poh Seo Quek, Lai Mei Tham, Lay Chin Tan, John Abisheganaden, Albert Yick Hou Lim

European Respiratory Journal Sep 2019, 54 (suppl 63) PA2874; DOI: 10.1183/13993003.congress-2019.PA2874
Comparison of efficacy and safety of twice-daily Glycopyrronium/Formoterol combination with once-daily Glycopyrronium in patients with moderate to severe COPD
Sundeep Salvi, Anand Kumar, Sumit Agrawal, Amrutlal Leuva, Vineet Shukla, Shrikant Deshpande, Santhalingum Balamurugan, Ajeet Singh, Sharad Tikkiwal, Sandeep Gupta, Sandesh Sawant, Abhijit Vaidya, Jaideep Gogtay

European Respiratory Journal Sep 2019, 54 (suppl 63) PA2476; DOI: 10.1183/13993003.congress-2019.PA2476
Improving COPD symptoms with umeclidinium/vilanterol and impact of baseline disease severity: the EMAX trial
François Maltais, Claus F. Vogelmeier, Isabelle H. Boucot, Leif Bjermer, Edward M. Kerwin, Ian P. Naya, Lee Tombs, Chris Compton, David A. Lipson, Paul Jones

European Respiratory Journal Sep 2019, 54 (suppl 63) PA2473; DOI: 10.1183/13993003.congress-2019.PA2473
Symptom improvement over time with umeclidinium/vilanterol versus monotherapy: a post-hoc analysis of the EMAX trial
Edward Kerwin, Claus F. Vogelmeier, François Maltais, Isabelle H. Boucot, Lee Tombs, Ian P. Naya, Paul Jones, Tom Keeley, David A. Lipson, Chris Compton, Leif Bjermer

European Respiratory Journal Sep 2019, 54 (suppl 63) PA2477; DOI: 10.1183/13993003.congress-2019.PA2477
Improving daily COPD symptoms, as measured using the E-RS, with umeclidinium/vilanterol versus monotherapy: the EMAX trial
Paul Jones, Leif Bjermer, Claus F Vogelmeier, François Maltais, Ian P Naya, Lee Tombs, Isabelle Boucot, Tom Keeley, David Lipson, Chris Compton, Edward M Kerwin

European Respiratory Journal Sep 2019, 54 (suppl 63) PA2474; DOI: 10.1183/13993003.congress-2019.PA2474

Main menu

User menu

Search

Bronchodilators

Pages

Contact us